Now that twitter has recovered from its downtime, a catch-up tweetorial on apixaban for AF in patients on dialysis for you.
This week, we will discuss the ongoing saga of blood pressure targets in patients with hypertension. This time its ESPRIT (Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing Risk of Vascular Events) making a case for case for intensive BP control in most hypertensive individuals, including those with a history of diabetes and stroke.
Now that twitter has recovered from its downtime, a catch-up tweetorial on apixaban for AF in patients on dialysis for you.
Many nephrologists make decisions about which anticoagulant (if any) to recommend for atrial fibrillation in patients on haemodialysis on a weekly basis.
— Nephrology Journal Club (@NephJC) March 6, 2023
And we finally have more randomised data!
Enjoy a rapid catch-up with #TenTweetNephJC pic.twitter.com/r99aAqPeiV